Insider trade

Director sold ~$258K of REGN shares in the open market

Traded Feb 19, 2026 · Filed Feb 23, 2026

~$258K
Reported value · 331 sh @ $780.45: 2,650
Holds after · shares reported: -6.1%
stock since the trade · S&P 500 +11.6%, $782.38 → $734.81 on Oct 1

Why it stands out

A board member of Regeneron Pharmaceuticals sold $258K of Regeneron Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 19, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 23, 2026

Director$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$258,329

Shares × reported transaction price

Timing vs results

20 days after results of Jan 30, 2026, 48 days before results of Apr 8, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $782.38 on Feb 19, 2026, within 4% of its 52-week high, little changed over the previous 30 trading days

52-week range $483.07 (Jun 5, 2025) to $812.27 (Jan 7, 2026), 91% of the way up, from 251 adjusted closes. 30 trading days earlier: $776.54 on Jan 6, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Dupixent on Feb 23, 2026, 4 days after this trade.

New use approved (efficacy supplement). Active ingredient: Dupilumab. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-0.7%	-1.0%	+0.3%
30 days	-2.0%	-6.2%	+4.2%
90 days	-17.8%	+9.2%	-27.0%
180 days	+7.3%	+11.1%	-3.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0001681643-26-000004
Filed / recorded: Feb 23, 2026, 9:55 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: REGENERON PHARMACEUTICALS, INC.
Issuer CIK: 872589
Ticker: REGN
Reporting person: Huda Y Zoghbi
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 19, 2026
Transaction code: S
Shares / units: 331
Price per share: $780.45
Acquired / disposed: Disposed (D)
Shares owned after: 2,650
Ownership form: Direct
Amendment: No

Footnotes from the filing

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.